Pasar al contenido principal

COMPORTAMIENTO FISICOQUIMICO Y BIOFARMACEUTICO DE NUEVAS NANOESTRUCTURAS NO LIPIDICAS PARA LA LIBERACION DE FARMACOS

PID2021-122187NB-C32

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Riluzole-Loaded Nanostructured Lipid Carriers for Hyperproliferative Skin Diseases

  • Llorente, Xavier
  • Esteruelas, Gerard
  • Bonilla, Lorena
  • Agudelo, Mariana Garnica
  • Filgaira, Ingrid
  • Lopez-Ramajo, Daniel
  • Gong, Ruoyi C.
  • Soler, Concepció
  • Espina, Marta
  • García, Maria Luisa
  • Manils, Joan
  • Pujol, Montserrat
  • Sánchez-López, Elena
Nanocarriers, and especially nanostructured lipid carriers (NLC), represent one of the most effective systems for topical drug administration. NLCs are biodegradable, biocompatible and provide a prolonged drug release. The glutamate release inhibitor Riluzole (RLZ) is a drug currently used for amyotrophic lateral sclerosis (ALS), with anti-proliferative effects potentially beneficial for diseases with excessive cell turnover. However, RLZ possesses low water solubility and high light-sensibility. We present here optimized NLCs loaded with RLZ (RLZ-NLCs) as a potential topical treatment. RLZ-NLCs were prepared by the hot-pressure homogenization method using active essential oils as liquid lipids, and optimized using the design of experiments approach. RLZ-NLCs were developed obtaining optimal properties for dermal application (mean size below 200 nm, negative surface charge and high RLZ entrapment efficacy). In vitro release study demonstrates that RLZ-NLCs allow the successful delivery of RLZ in a sustained manner. Moreover, RLZ-NLCs are not angiogenic and are able to inhibit keratinocyte cell proliferation. Hence, a NLCs delivery system loading RLZ in combination with natural essential oils constitutes a promising strategy against keratinocyte hyperproliferative conditions., This research was funded by the Spanish Ministry of Science and Innovation (PID2021-122187NB-C32 to M.G., PID2020-114477RB-I00 to C.S. and PID2021-126249OA-I00 to J.M. from the MCIN/ AEI /10.13039/501100011033)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Novel nanostructured lipid carriers loading Apigenin for anterior segment ocular pathologies

  • Bonilla-Vidal, L.
  • Espina, M.
  • García, M.L.
  • Baldomà, L.
  • Badia, J.
  • González, J.A.
  • Delgado, L.M.
  • Gliszczyńska, A.
  • Souto, E.B.
  • Sánchez-López, E.
This research was supported by the Spanish Ministry of Science and Innovation (PID2021-122187NB-C32) and a Llavors project (LLAV0004). EBS acknowledges FCT—Fundaçao para a Ciencia e a Tecnologia, I.P., in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of the Research Unit on Applied Molecular Biosciences—UCIBIO and the project LA/P/0140/ 2020 of the Associate Laboratory Institute for Health and Bioeconomy—i4HB. E.S.-L. acknowledges the support of Grants for the Requalification of the Spanish University System., Dry eye disease (DED) is a chronic multifactorial disorder of the ocular surface caused by tear film dysfunction and constitutes one of the most common ocular conditions worldwide. However, its treatment remains unsatisfactory. While artificial tears are commonly used to moisturize the ocular surface, they do not address the underlying causes of DED. Apigenin (APG) is a natural product with anti-inflammatory properties, but its low solubility and bioavailability limit its efficacy. Therefore, a novel formulation of APG loaded into biodegradable and biocompatible nanoparticles (APG-NLC) was developed to overcome the restricted APG stability, improve its therapeutic efficacy, and prolong its retention time on the ocular surface by extending its release. APG-NLC optimization, characterization, biopharmaceutical properties and therapeutic efficacy were evaluated. The optimized APG-NLC exhibited an average particle size below 200 nm, a positive surface charge, and an encapsulation efficiency over 99 %. APG-NLC exhibited sustained release of APG, and stability studies demonstrated that the formulation retained its integrity for over 25 months. In vitro and in vivo ocular tolerance studies indicated that APG-NLC did not cause any irritation, rendering them suitable for ocular topical administration. Furthermore, APG-NLC showed non-toxicity in an epithelial corneal cell line and exhibited fast cell internalization. Therapeutic benefits were demonstrated using an in vivo model of DED, where APG-NLC effectively reversed DED by reducing ocular surface cellular damage and increasing tear volume. Anti-inflammatory assays in vivo also showcased its potential to treat and prevent ocular inflammation, particularly relevant in DED patients. Hence, APG-NLC represent a promising system for the treatment and prevention of DED and its associated inflammation., info:eu-repo/semantics/publishedVersion